FDA Approves First-Ever Treatment for Rare Genetic Thyroid Disorder MCT8 Deficiency
Federal health regulators have cleared the first-ever treatment designed specifically to address a rare and life-limiting genetic thyroid hormone disorder. The U.S. Food and Drug Administration (FDA) announced the approval of tiratricol, marketed under the brand name Emcitate, to treat peripheral thyrotoxicosis in patients diagnosed with monocarboxylate transporter 8 (MCT8) deficiency.
Also recognized as Allan-Herndon-Dudley syndrome, MCT8 deficiency is an X-linked genetic condition caused by mutations in the SLC16A2 gene. Because the condition primarily affects males, it disrupts normal cell-surface transport proteins. This genetic disruption creates a severe and unusual imbalance throughout the body: the central nervous system becomes starved of necessary thyroid hormones, while peripheral tissues and organs are simultaneously overexposed to active T3 hormones.
This dual imbalance results in significant neurodevelopmental challenges, often leaving patients unable to sit or walk independently, alongside ongoing, damaging stress on the cardiovascular and metabolic systems.
According to Hylton Joffe, MD, MMSc, director of the Division of Clinical Evaluation and Pharmacology/Toxicology in the FDA’s Center for Drug Evaluation and Research, treating the condition has historically presented a major obstacle. Dr. Joffe explained that the fundamental difficulty has been that the specific protein responsible for carrying thyroid hormone into cells fails to function properly in these patients.
The newly approved medication successfully bypasses that barrier. Its active ingredient, tiratricol, enters cells independently without requiring the defective transporter protein, ultimately helping to reduce elevated blood thyroid hormone levels.
The regulatory approval was supported by data from two separate clinical investigations: the randomized, placebo-controlled ReTRIACt trial, which evaluated 20 participants aged 5 to 31 years, and an open-label trial involving 46 participants ranging from 10 months to nearly 67 years of age.
Findings from both studies demonstrated that tiratricol successfully reduced excess thyroid hormone levels circulating in the blood. Furthermore, the therapy improved cardiovascular and metabolic metrics affected by abnormal thyroid activity, including heart rate and systolic blood pressure.
Andrew Bauer, MD, principal investigator of the ReTRIACt trial, noted the significance of the milestone in a statement released by drug manufacturer Egetis Therapeutics. Having witnessed the profound difficulties the complex disorder inflicts on patients and their families, Dr. Bauer emphasized that the approval supplies physicians with an authorized therapeutic option for the first time, marking a substantial step forward for the MCT8 deficiency community.
Administration, Side Effects, and Availability
Tiratricol is administered as a once-daily liquid suspension. It can be taken orally or delivered through a feeding tube for patients who experience difficulties with swallowing.
Regarding safety, clinical data revealed that the most frequent adverse effects linked to the medication include diarrhea, vomiting, rash, and excessive sweating, clinically known as hyperhidrosis.
Because of its specific mechanism, the drug label features a prominent boxed warning explicitly stating that tiratricol is not approved or intended for weight loss or the treatment of obesity. Prescribing information also cautions against using the medication in individuals with primary hyperthyroidism, or administering it concurrently with other thyroid medications. Additional warnings highlight potential risks of inducing thyrotoxicosis and interfering with standard laboratory tests used to measure T3 levels.
According to Egetis Therapeutics, tiratricol is expected to become commercially available to patients in the United States within eight to ten weeks.
Source: MedPage Today
